Other indications (e.g. myeloproliferative diseases)
Follow-Up Treatment
This is an open-label, randomized (2:1), multicenter, Phase 3 study of imetelstat compared with BAT in approximately 320 participants with intermediate-2 or high-risk MF (primary MF [PMF], post-ET-MF [PET-MF], or post-PV-MF [PPV-MF]) who are refractory to JAK-inhibitor
treatment.
This is an open-label, randomized (2:1), multicenter, Phase 3 study of imetelstat compared with BAT in approximately 320 participants with intermediate-2 or high-risk MF (primary MF [PMF], post-ET-MF [PET-MF], or post-PV-MF [PPV-MF]) who are refractory to JAK-inhibitor
treatment.
